The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed well enough in the COMPARE-TAVI 1 randomized trial, but its rates of ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter ...

Edwards’ INSPIRIS RESILIA and SAPIEN 3 Ultra RESILIA valves are supported ... have been treated with Edwards’ surgical or TAVR valves with RESILIA tissue, reflecting its expanding role in ...

Edwards Lifesciences has received Europe’s CE mark for its transcatheter mitral valve replacement system, Sapien M3, the company said Monday. The device is designed for people with symptomatic ...